SEC Company Response from CASSAVA SCIENCES INC (FLNA) (CIK 0001069530) (FLNA) — Dec 18, 2009
CASSAVA SCIENCES INC (FLNA) (CIK 0001069530)
Date: Dec. 18, 2009 · CIK: 0001069530 · Accession: 0001193125-09-255696
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-29959
Referenced dates: December 14, 2009, December 4, 2009
Letter
Division of Corporation Finance Attention: Suzanne Hayes Re: Pain Therapeutics, Inc. Form 10-K filed for the Year Ended December 31, 2008 Filed February 13, 2009 File No. 000-29959
Dear Ms. Hayes:
Pain Therapeutics, Inc. (the “Company”) provides this response to the comments of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in the Staff’s letter dated December 14, 2009 (the “Staff Letter”), relating to the above-referenced Form 10-K filed by the Company. In response to the Staff’s comments, we have reproduced below the comments set forth in the Staff Letter and followed each comment with our response. The numbered paragraphs of this letter set forth below correspond to the numbered paragraphs of the Staff Letter. References to “we,” “our” or “us” mean the Company or its advisors, as the context may require.
Form 10-K, filed 02/13/2009
Intellectual Property, page 5
COMMENT 1: We note your response to comment 1. Please confirm that you intend to provide this information in your “Intellectual Property” discussion in your next 10-K.
RESPONSE: We hereby confirm that we will provide the information included in our letter dated December 4, 2009 in response to the SEC’s Comment 1 in our next Annual Report on Form 10-K for the fiscal year ending December 31, 2009.
Schedule 14A, filed 04/06/2009
Compensation Discussion and Analysis, page 11
COMMENT 2: To the extent you continue to state that you use purchased surveys and/or internally generated surveys for determining compensation, please confirm that you will indentify the purchased surveys and identify the companies included in your internally generated surveys and explain how you used the data generated from these surveys.
RESPONSE: We hereby confirm that to the extent we continue to state that we use purchased surveys and/or internally generated surveys for determining compensation, we will identify the purchased surveys and identify the companies included in our internally generated surveys and explain how we used the data generated from these surveys.
U.S. Securities and Exchange Commission
December 18, 2009
Page 2
Should you have any further questions or comments, please do not hesitate to contact me at (650) 645-1930.
Sincerely,
Pain Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Correspondence Letter
December 18, 2009
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Mail Stop 4720
Washington, D.C. 20549
Attention:
Suzanne Hayes
Jeffrey P. Riedler
Re:
Pain Therapeutics, Inc.
Form 10-K filed for the Year Ended December 31, 2008
Filed February 13, 2009
File No. 000-29959
Dear Ms. Hayes:
Pain Therapeutics, Inc. (the “Company”) provides this response to the comments of the staff (the “Staff”)
of the Securities and Exchange Commission (the “Commission”) contained in the Staff’s letter dated December 14, 2009 (the “Staff Letter”), relating to the above-referenced Form 10-K filed by the Company.
In response to the Staff’s comments, we have reproduced below the comments set forth in the Staff Letter and followed each comment with our response. The numbered paragraphs of this letter set forth below correspond to the numbered paragraphs
of the Staff Letter. References to “we,” “our” or “us” mean the Company or its advisors, as the context may require.
Form 10-K, filed 02/13/2009
Intellectual Property, page 5
COMMENT 1: We note your response to comment 1. Please confirm that you intend to provide this information in your
“Intellectual Property” discussion in your next 10-K.
RESPONSE: We hereby confirm that we will
provide the information included in our letter dated December 4, 2009 in response to the SEC’s Comment 1 in our next Annual Report on Form 10-K for the fiscal year ending December 31, 2009.
Schedule 14A, filed 04/06/2009
Compensation Discussion and Analysis, page 11
COMMENT 2: To the extent you
continue to state that you use purchased surveys and/or internally generated surveys for determining compensation, please confirm that you will indentify the purchased surveys and identify the companies included in your internally generated surveys
and explain how you used the data generated from these surveys.
RESPONSE: We hereby confirm that to
the extent we continue to state that we use purchased surveys and/or internally generated surveys for determining compensation, we will identify the purchased surveys and identify the companies included in our internally generated surveys and
explain how we used the data generated from these surveys.
U.S. Securities and Exchange Commission
December 18, 2009
Page 2
Should you have any further questions or comments, please do not hesitate to contact me at (650) 645-1930.
Sincerely,
Pain Therapeutics, Inc.
/s/ Peter S. Roddy
Peter S. Roddy
Vice President and Chief Financial Officer
cc:
Michael O’Donnell, Esq.
Gavin McCraley, Esq.
Wilson Sonsini Goodrich & Rosati, P.C.